Electra Therapeutics (ETRA) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $8.75, -2.13% vs the prior close of $8.94.
- Volume 179.60K shares, 0.2x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ETRA dips 2.1% to $8.75. Closed at $8.75, -2.13% vs the prior close of $8.94. Day range $8.58–$8.99, opened at $8.97.
ETRA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — ETRA dips 2.1% to $8.75
- Closed at $8.75, -2.13% vs the prior close of $8.94. Day range $8.58–$8.99, opened at $8.97.
- Volume was 179.60K shares, 0.2x its 50-day average of 836.37K — lighter than usual.
- 52-week range $8.50–$15.50; today's close sits at 4% of that range, 43.5% below the 52-week high.
Oct 14, 2026 — ETRA jumps 3.8% to $8.94
- Closed at $8.94, +3.83% vs the prior close of $8.61. Day range $8.50–$9.47, opened at $8.69.
- Volume was 521.00K shares, 0.6x its 50-day average of 853.89K.
- 52-week range $8.50–$15.50; today's close sits at 6% of that range, 42.3% below the 52-week high.
Oct 13, 2026 — ETRA slides 7.6% to $8.61
- Closed at $8.61, -7.62% vs the prior close of $9.32. Day range $8.57–$9.80, opened at $9.39.
- Volume was 552.30K shares, 0.6x its 50-day average of 871.63K.
- 52-week range $8.57–$15.50; today's close sits at 1% of that range, 44.5% below the 52-week high.
Oct 12, 2026 — ETRA jumps 3.1% to $9.32
- Closed at $9.32, +3.10% vs the prior close of $9.04. Day range $8.78–$9.60, opened at $8.99.
- Volume was 346.70K shares, 0.4x its 50-day average of 904.44K — lighter than usual.
- 52-week range $8.63–$15.50; today's close sits at 10% of that range, 39.9% below the 52-week high.
Oct 9, 2026 — ETRA dips 1.1% to $9.04, 3 down days in a row
- Closed at $9.04, -1.09% vs the prior close of $9.14. Day range $8.68–$9.30, opened at $9.13.
- Volume was 778.50K shares, 0.9x its 50-day average of 912.83K.
- 52-week range $8.63–$15.50; today's close sits at 6% of that range, 41.7% below the 52-week high.
- That makes 3 straight losses.
Oct 8, 2026 — ETRA ends flat (-0.2%) to $9.14
- Closed at $9.14, -0.22% vs the prior close of $9.16. Day range $8.63–$10.12, opened at $9.10.
- Volume was 408.00K shares, 0.4x its 50-day average of 948.89K — lighter than usual.
- 52-week range $8.63–$15.50; today's close sits at 7% of that range, 41.0% below the 52-week high.
Oct 7, 2026 — ETRA slides 6.7% to $9.16
- Closed at $9.16, -6.72% vs the prior close of $9.82. Day range $8.92–$9.73, opened at $9.72.
- Volume was 407.30K shares, 0.4x its 50-day average of 990.55K — lighter than usual.
- 52-week range $8.92–$15.50; today's close sits at 4% of that range, 40.9% below the 52-week high.
Oct 6, 2026 — ETRA rises 0.8% to $9.82
- Closed at $9.82, +0.82% vs the prior close of $9.74. Day range $9.35–$9.95, opened at $9.68.
- Volume was 276.20K shares, 0.3x its 50-day average of 1.05M — lighter than usual.
- 52-week range $9.28–$15.50; today's close sits at 9% of that range, 36.6% below the 52-week high.
Oct 5, 2026 — ETRA slides 6.1% to $9.74, 4 down days in a row
- Closed at $9.74, -6.08% vs the prior close of $10.37. Day range $9.28–$10.46, opened at $10.46.
- Volume was 334.40K shares, 0.3x its 50-day average of 1.12M — lighter than usual.
- 52-week range $9.28–$15.50; today's close sits at 7% of that range, 37.2% below the 52-week high.
- That makes 4 straight losses.
Oct 2, 2026 — ETRA dips 2.9% to $10.37, 3 down days in a row
- Closed at $10.37, -2.90% vs the prior close of $10.68. Day range $9.88–$11.13, opened at $10.75.
- Volume was 696.60K shares, 0.6x its 50-day average of 1.16M.
- 52-week range $9.88–$15.50; today's close sits at 9% of that range, 33.1% below the 52-week high.
- That makes 3 straight losses.
ETRA latest news & SEC filings
Every SEC filing by or about ETRA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 28, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 28, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 25, 2026 · Form SCHEDULE 13D — Activist-style stake (13D)
Activist-style stake (13D) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Gordon Carl L converted 2,002,310 shares on Sep 21, 2026; now holds 2,002,310
- Gordon Carl L converted 1,087,934 shares on Sep 21, 2026; now holds 3,090,244
- Gordon Carl L converted 1,703,314 shares on Sep 21, 2026; now holds 4,793,558
- Gordon Carl L bought 333,333 shares at $15.00 (≈$5.00M) on Sep 21, 2026; now holds 5,126,891
- Gordon Carl L converted 758,279 shares on Sep 21, 2026; now holds 758,279
- Gordon Carl L bought 1,000,000 shares at $15.00 (≈$15.00M) on Sep 21, 2026; now holds 1,758,279
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Orbimed Advisors Llc & Orbimed Capital Gp Vii Llc & Orbimed Genesis Gp Llc converted 2,002,310 shares on Sep 21, 2026; now holds 2,002,310
- Orbimed Advisors Llc & Orbimed Capital Gp Vii Llc & Orbimed Genesis Gp Llc converted 1,087,934 shares on Sep 21, 2026; now holds 3,090,244
- Orbimed Advisors Llc & Orbimed Capital Gp Vii Llc & Orbimed Genesis Gp Llc converted 1,703,314 shares on Sep 21, 2026; now holds 4,793,558
- Orbimed Advisors Llc & Orbimed Capital Gp Vii Llc & Orbimed Genesis Gp Llc bought 333,333 shares at $15.00 (≈$5.00M) on Sep 21, 2026; now holds 5,126,891
- Orbimed Advisors Llc & Orbimed Capital Gp Vii Llc & Orbimed Genesis Gp Llc converted 758,279 shares on Sep 21, 2026; now holds 758,279
- Orbimed Advisors Llc & Orbimed Capital Gp Vii Llc & Orbimed Genesis Gp Llc bought 1,000,000 shares at $15.00 (≈$15.00M) on Sep 21, 2026; now holds 1,758,279
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 21, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 21, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Koe Gary S. converted 63,656 shares on Sep 21, 2026; now holds 63,656
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 21, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Stagliano Nancy converted 255,635 shares on Sep 21, 2026; now holds 255,635
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 21, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Parry Graham converted 85,504 shares on Sep 21, 2026; now holds 85,504
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 21, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Sep 21, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
- Item 8.01 — Reported other events the company considers important.
Sep 18, 2026 · Form 424B4 — Final prospectus with offering price
Final prospectus with offering price
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 18, 2026 · Form 8-A12B — 8-A12B filing
8-A12B filing
Sep 17, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Things to know before you trade ETRA
- How much it moves: over the last 20 sessions the average daily move was 3.47% (largest 7.6%). That is a volatile stock.
- Liquidity: about 803.53K shares (≈$7.03M) trade per day on average.
- 52-week position: $8.75 vs a range of $8.50–$15.50 (4% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 8 open-market buys, 0 sales; latest: Carl L Gordon bought 333,333 shares on Sep 21, 2026.
- Latest filings: 8-K Sep 21, 2026.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
ETRA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 8.97 | 8.99 | 8.58 | 8.75 | 179.60K |
| Oct 14, 2026 | 8.69 | 9.47 | 8.50 | 8.94 | 521.00K |
| Oct 13, 2026 | 9.39 | 9.80 | 8.57 | 8.61 | 552.30K |
| Oct 12, 2026 | 8.99 | 9.60 | 8.78 | 9.32 | 346.70K |
| Oct 9, 2026 | 9.13 | 9.30 | 8.68 | 9.04 | 778.50K |
| Oct 8, 2026 | 9.10 | 10.12 | 8.63 | 9.14 | 408.00K |
| Oct 7, 2026 | 9.72 | 9.73 | 8.92 | 9.16 | 407.30K |
| Oct 6, 2026 | 9.68 | 9.95 | 9.35 | 9.82 | 276.20K |
| Oct 5, 2026 | 10.46 | 10.46 | 9.28 | 9.74 | 334.40K |
| Oct 2, 2026 | 10.75 | 11.13 | 9.88 | 10.37 | 696.60K |
| Oct 1, 2026 | 11.14 | 11.58 | 10.46 | 10.68 | 1.26M |
| Sep 30, 2026 | 11.37 | 12.09 | 11.23 | 11.25 | 925.70K |
| Sep 29, 2026 | 11.21 | 11.94 | 11.00 | 11.35 | 715.60K |
| Sep 28, 2026 | 11.52 | 11.91 | 11.14 | 11.32 | 537.10K |
| Sep 25, 2026 | 11.70 | 12.75 | 11.27 | 11.55 | 438.40K |
| Sep 24, 2026 | 12.54 | 13.56 | 11.71 | 11.82 | 445.20K |
| Sep 23, 2026 | 13.56 | 14.18 | 12.50 | 12.67 | 875.40K |
| Sep 22, 2026 | 13.88 | 14.12 | 13.11 | 13.62 | 439.70K |
| Sep 21, 2026 | 13.94 | 14.48 | 13.48 | 13.92 | 813.20K |
| Sep 18, 2026 | 15.00 | 15.50 | 13.25 | 13.25 | 5.12M |
About Electra Therapeutics
Electra Therapeutics (ETRA) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in SOUTH SAN FRANCISCO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 2088082.
ETRA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Quehuong (Kathy) Dong | President & CEO | Sep 21, 2026 |
| Matthew K Fust | Director | Sep 18, 2026 |
| Carl L Gordon | Director | Sep 23, 2026 |
| Advisors Llc Orbimed | Director | Sep 23, 2026 |
| Capital Gp Vii Llc Orbimed | Director | Sep 23, 2026 |
| Genesis Gp Llc Orbimed | Director | Sep 23, 2026 |
| Nancy Stagliano | Director | Sep 21, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Christopher William Clark | Chief Financial Officer | Sep 18, 2026 |
| Kim-Hien Dao | Chief Medical Officer | Sep 18, 2026 |
| Quehuong (Kathy) Dong | President & CEO | Sep 21, 2026 |
| Gary S. Koe | Chief Technical Officer | Sep 21, 2026 |
| Graham Parry | Chief Scientific Officer | Sep 21, 2026 |
| David J. Tucker | Principal Accounting Officer | Sep 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 21, 2026 | Carl L Gordon | Buy | 333,333 | $15.00 |
| Sep 21, 2026 | Carl L Gordon | Buy | 1,000,000 | $15.00 |
| Sep 21, 2026 | Capital Gp Vii Llc Orbimed | Buy | 1,000,000 | $15.00 |
| Sep 21, 2026 | Capital Gp Vii Llc Orbimed | Buy | 333,333 | $15.00 |
| Sep 21, 2026 | Genesis Gp Llc Orbimed | Buy | 1,000,000 | $15.00 |
| Sep 21, 2026 | Genesis Gp Llc Orbimed | Buy | 333,333 | $15.00 |
| Sep 21, 2026 | Advisors Llc Orbimed | Buy | 1,000,000 | $15.00 |
| Sep 21, 2026 | Advisors Llc Orbimed | Buy | 333,333 | $15.00 |
ETRA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
ETRA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on ETRA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.